These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 7514044)

  • 1. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
    Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
    Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
    Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
    Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
    Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
    Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced fibrinolytic activity during the course of hemodialysis.
    Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
    Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
    Cucuianu M; Knauer O; Roman S
    Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
    Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
    Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
    J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
    Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
    Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.